The Carlyle Group’s $435m private equity deal with Unchained Labs was the medical devices industry’s biggest internet of things deal of Q2 2021 as internet of things deals worth $820.9m were announced globally in the quarter, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked an increase of 751.7% over the previous quarter and a rise of 111.2% when compared with the last four-quarter average of $388.64m.

In terms of number of internet of things deals, the sector saw a rise of 14.29% with 22 deals in Q2 2021 against the average of 19.25 deals in the last four-quarters.

In value terms, North America led the activity with internet of things deals worth $524.29m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

medical devices industry internet of things deals in Q2 2021: Top deals

The top five medical devices industry internet of things deals accounted for 89.4% of the overall value during Q2 2021.

The combined value of the top five internet of things deals stood at $734m, against the overall value of $820.9m recorded for the quarter.

The top five medical devices industry internet of things deals of Q2 2021 tracked by GlobalData were:

1) The Carlyle Group’s $435m private equity deals with Unchained Labs

2) The $130m venture financing with Huma Therapeutics by HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures

3) Credit Suisse Entrepreneur Capital, Endeavour Vision, Federated Hermes Kaufmann Fund, GMS Capital, Kingdon Capital Management, SchroderBank AG, Tandem Diabetes Care, VI Partners and Ypsomed’s $115m venture financing of CeQur

4) The $34m venture financing of Zus Health by Andreessen Horowitz, F-Prime, Martin Ventures, Maverick Ventures, Oxeon Investments and Rock Health

5) Atinum Investment, KB Investment, Korea Investment Partners, LB Investment, MORU Asset Management and Soo Investment Capital’s venture financing with Sky Labs for $20m.